Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to performance of any trial-related activity~* Male sex 18 years of age or older~* At least 2 voids every night in a consecutive 3-day period during the screening period based on the patient diary.~Exclusion Criteria:~* Evidence of severe daytime voiding dysfunction defined as: Urge urinary incontinence (more than 1 episode/day in the 3-day diary period), Urgency (more than 1 episode/day in the 3-day diary period), Frequency (more than 8 daytime voids/day in the 3-day diary period)~* Interstitial Cystitis~* Chronic prostatitis/chronic pelvic pain syndrome~* Suspicion of bladder outlet obstruction (BOO) or a urine flow of less than 5 mL/s as confirmed by uroflowmetry performed after suspicion of BOO~* Surgical treatment, including transurethral resection, for BOO or benign prostatic hyperplasia within the past 6 months~* Urinary retention or a post void residual volume in excess of 250 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention~* Habitual or psychogenic fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours~* Central or nephrogenic diabetes insipidus.~* Syndrome of inappropriate anti-diuretic hormone.~* Current or a history of urologic malignancies e.g. urothelium, prostate, or kidney cancer~* Genitourinary tract pathology e.g. infection or stone in the bladder and urethra causing symptoms~* Neurogenic detrusor activity (detrusor overactivity)~* Suspicion or evidence of cardiac failure~* Uncontrolled hypertension~* Uncontrolled diabetes mellitus~* Hyponatraemia: Serum sodium level must be within normal limits~* Renal insufficiency: Serum creatinine must be within normal limits and estimated glomerular filtration rate must be more than or equal to 50 mL/min~* Hepatic and/or biliary diseases: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL~* History of obstructive sleep apnea~* Previous desmopressin treatment for nocturia~* Treatment with another investigational product within 3 months prior to screening~* Concomitant treatment with any prohibited medication, i.e. loop diuretics (furosemide, torsemide, ethacrynic acid) and any other investigational drug~* Known alcohol or substance abuse~* Work or lifestyle that may interfere with regular nighttime sleep e.g. shift workers~* Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin 50 μg Double-Blind / 100 μg Open-Label (Type: EXPERIMENTAL): Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
- Desmopressin 75 μg Double-Blind / 100 μg Open-Label (Type: EXPERIMENTAL): Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
- Placebo Double-Blind / Desmopressin 100 μg Open-Label (Type: PLACEBO_COMPARATOR): Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).